Genomic Health's Q3 Revenues Rise 77 Percent on Oncotype DX Sales | GenomeWeb
NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market on Wednesday that its third-quarter revenues rose 77 percent due to increased sales of its Oncotype DX breast cancer assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.